Company Overview - Zhengxiang Pharmaceutical (Nanjing) Group Co., Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for unmet medical needs in viral infectious diseases, oncology, and inflammatory diseases [4] - The core product, Marcilosavir (ZX-7101A), is a targeted inhibitor of the influenza virus PA endonuclease, which received NDA approval from the National Medical Products Administration (NMPA) for treating adult influenza in July 2025 [4][5] - The company has developed a pipeline of six drug assets, including Marcilosavir tablets, a pediatric formulation, and candidates for HPV, HSV, and solid tumors [4] Financial Information - The company reported no revenue for the fiscal years 2024 and the nine months ending September 30, 2024, and 2025 [7] - The net losses for the fiscal years 2024 and the nine months ending September 30, 2024, and 2025 were approximately RMB 145 million, RMB 127 million, and RMB 145 million, respectively [8][9] Market Overview - The global market for influenza treatment and prevention drugs is projected to reach USD 4.8 billion in 2024, with China contributing USD 1.7 billion [10] - By 2035, the market size is expected to grow to USD 10.5 billion, with China contributing USD 2.5 billion [10] - The Chinese market for antiviral drugs for influenza is estimated to be RMB 5.7 billion in 2024, with PA inhibitors accounting for RMB 0.9 billion [17] Drug Pipeline and Development - The company is expanding the indications for Marcilosavir to include adolescents and post-exposure prophylaxis, with milestones set for NDA submissions in 2026 [4] - The pipeline includes a clinical-stage candidate for solid tumors (ZX-8177) and candidates for HSV and autoimmune diseases, with IND submissions planned for 2026 and 2027 [4][17] Board of Directors - The board consists of seven members, including two executive directors, two non-executive directors, and three independent non-executive directors [20] Shareholding Structure - As of January 23, 2026, key shareholders include Dr. Yang and Dr. Hao, who collectively hold approximately 22.76% of the voting rights, and Enran Venture Capital, which holds 18.39% of the shares [22]